Survival Following Hospitalization with Hepatocellular Carcinoma Among People Notified with Hepatitis B or C Virus in Australia (2000-2014)

Overview

Journal Hepatol Commun

Specialty Gastroenterology

Date 2018 Feb 7

PMID 29404490

Citations 2

Authors

Reem Waziry

Jason Grebely

Janaki Amin

Maryam Alavi

Behzad Hajarizadeh

Jacob George

Gail V Matthews

Matthew Law

Gregory J Dore

Affiliations

Soon will be listed here.

Abstract

We assessed trends in HCC survival in patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection in New South Wales, Australia. Data on HBV (n = 54,399) and HCV (n = 96,908) notifications (1993-2012) were linked to a hospitalization database (July 2000-June 2014), the New South Wales Cancer Registry, and the New South Wales Death Registry. A total of 725 (1.3%) first HBV-hepatocellular carcinoma (HCC) and 1,309 (1.4%) first HCV-HCC hospitalizations were included. Death occurred in 60.4% of HBV-HCC and 69.6% of HCV-HCC patients. Median survival following first HBV-HCC hospitalization improved from 0.6 years (95% confidence interval [CI] 0.39-1.28) in 2000-2004 to 2.8 years (1.54-5.54) in 2010-2014. Median survival following first HCV-HCC hospitalization was 0.8 years (0.45-1.33) in 2000-2004 and 0.9 (0.67-1.18) in 2010-2014. One-year HBV-HCC survival in 2010-2014 compared to 2000-2004 improved for those with (94% versus 81%) and without (42% versus 33%) potentially curative procedures (liver resection, liver transplantation, and radiofrequency ablation). Factors associated with improved survival following HBV-HCC were later study period (hazard ratio [HR] = 0.74; 95% CI, 0.57-0.97) and potentially curative procedures (liver resection, liver transplantation, and radiofrequency ablation) (HR = 0.23; 95% CI, 0.17-0.29), while male gender (HR = 1.37; 95% CI, 1.03-1.82), human immunodeficiency virus coinfection (HR = 3.06; 95% CI, 1.36-6.88), and Charlson Comorbidity Index ≥3 (HR = 1.81; 95% CI, 1.35-2.40) were associated with reduced survival. Factors associated with improved survival following HCC-HCV were Asia-Pacific country of birth (HR = 0.68; 95% CI, 0.55-0.84) and potentially curative procedures (HR = 0.21; 95% CI, 0.17-0.25), while age (HR = 1.01; 95% CI, 1.01-1.02), rural place of residence (HR = 1.46; 95% CI, 1.22-1.74), and human immunodeficiency virus coinfection (HR = 2.71; 95% CI, 1.19-6.15) were associated with reduced survival. : All-cause survival following HBV-HCC has improved considerably, suggesting an impact of more effective antiviral therapy and earlier HCC diagnosis; in contrast, all-cause survival for HCV-HCC is unchanged. ( 2017;1:736-747).

Citing Articles

Hepatocellular carcinoma amongst Aboriginal and Torres Strait Islander peoples of Australia.

Wigg A, Narayana S, Hartel G, Medlin L, Pratt G, Powell E EClinicalMedicine. 2021; 36:100919.

PMID: 34142069 PMC: 8187829. DOI: 10.1016/j.eclinm.2021.100919.

HBV upregulates AP-1 complex subunit mu-1 expression via the JNK pathway to promote proliferation of liver cancer cells.

Kou Y, Yan X, Liu Q, Wei X, Zhang B, Li X Oncol Lett. 2019; 18(1):456-464.

PMID: 31289517 PMC: 6540315. DOI: 10.3892/ol.2019.10291.

References

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Hann H, Coben R, Brown D, Needleman L, Rosato E, Min A . A long-term study of the effects of antiviral therapy on survival of patients with HBV-associated hepatocellular carcinoma (HCC) following local tumor ablation. Cancer Med. 2014; 3(2):390-6. PMC: 3987088. DOI: 10.1002/cam4.197. View

Murray C, Lopez A . Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997; 349(9064):1498-504. DOI: 10.1016/S0140-6736(96)07492-2. View

Chan A, Poon R, Ng K, Lo C, Fan S, Wong J . Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening. Ann Surg. 2008; 247(4):666-73. DOI: 10.1097/SLA.0b013e31816a747a. View

Changchien C, Chen C, Yen Y, Wang J, Hu T, Lee C . Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol. 2008; 43(2):159-70. DOI: 10.1007/s00535-007-2134-9. View

Amin J, Law M, Bartlett M, Kaldor J, Dore G . Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet. 2006; 368(9539):938-45. DOI: 10.1016/S0140-6736(06)69374-4. View

Kuo Y, Lu S, Chen C, Cheng Y, Lin C, Hung C . Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer. 2010; 46(4):744-51. DOI: 10.1016/j.ejca.2009.12.018. View

Malagari K, Alexopoulou E, Chatzimichail K, Hall B, Koskinas J, Ryan S . Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging. 2007; 33(5):512-9. DOI: 10.1007/s00261-007-9334-x. View

. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 385(9963):117-71. PMC: 4340604. DOI: 10.1016/S0140-6736(14)61682-2. View

10.

. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol. 2016; 65(4):734-740. DOI: 10.1016/j.jhep.2016.05.045. View

11.

Walter S, Thein H, Gidding H, Amin J, Law M, George J . Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. J Gastroenterol Hepatol. 2011; 26(12):1757-64. DOI: 10.1111/j.1440-1746.2011.06785.x. View

12.

Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S . Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016; 65(4):719-726. DOI: 10.1016/j.jhep.2016.04.008. View

13.

Liang P, Wang Y . Microwave ablation of hepatocellular carcinoma. Oncology. 2007; 72 Suppl 1:124-31. DOI: 10.1159/000111718. View

14.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

15.

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

16.

Thein H, Khoo E, Campitelli M, Zaheen A, Yi Q, De P . Trends in relative survival in patients with a diagnosis of hepatocellular carcinoma in Ontario: a population-based retrospective cohort study. CMAJ Open. 2015; 3(2):E208-16. PMC: 4565177. DOI: 10.9778/cmajo.20140118. View

17.

Witjes C, Karim-Kos H, Visser O, van den Akker S, de Vries E, IJzermans J . Hepatocellular carcinoma in a low-endemic area: rising incidence and improved survival. Eur J Gastroenterol Hepatol. 2012; 24(4):450-7. DOI: 10.1097/MEG.0b013e32835030ce. View

18.

Waziry R, Grebely J, Amin J, Alavi M, Hajarizadeh B, George J . Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014). J Hepatol. 2016; 65(6):1086-1093. DOI: 10.1016/j.jhep.2016.08.010. View

19.

Llovet J, Burroughs A, Bruix J . Hepatocellular carcinoma. Lancet. 2003; 362(9399):1907-17. DOI: 10.1016/S0140-6736(03)14964-1. View

20.

Moorman A, Xing J, Ko S, Rupp L, Xu F, Gordon S . Late diagnosis of hepatitis C virus infection in the Chronic Hepatitis Cohort Study (CHeCS): Missed opportunities for intervention. Hepatology. 2014; 61(5):1479-84. PMC: 5675516. DOI: 10.1002/hep.27365. View